equilliumbio.com (EQ) Cash Funds per Share

Equillium, Inc. faces the threat of clinical trial failure and requires an influx of external investment. The cash per share metric reflects the depletion of reserves, with the value recorded at 0.66. Business resilience is constrained by fierce competition in immunology, a high burn rate, and a dependence on funding from strategic partners.
Analytical breakdowns for equilliumbio.com (EQ)

For Equillium, Inc., which conducts costly biotech research, liquidity reserves are critical until patents are commercialized. This metric is calculated by dividing total cash holdings by the number of shares outstanding. The current cash per share stands at 0.66, reflecting the available resources for operational activities. The trend in cash per share allows for tracking the capital burn rate. The stability of this value confirms the financial resilience of the licensing model.